Abstract
Cancer stem cells (CSCs) represent a small subpopulation of the bulk of a tumor. The CSCs possess the characteristics of self-renewal, clonal repopulation and resistance to conventional therapies, and thereby contribute to cancer metastasis and relapse. Moreover, CSCs establish homeostasis under stress via autophagy, endoplasmic reticulum (ER)-stress-mediated unfolded protein response (UPR) pathways, and mitophagy. Recent evidence indicate that besides many protein molecules, the noncoding RNAs (ncRNAs) also play a significant role in CSC growth and maintenance, as well as in cancer metastasis and therapeutic resistance. Therefore, targeting the CSCs has evolved as an important strategy for cancer therapy. Recent advancements in cancer immunotherapy has shown excellent application of its potential in targeting CSCs. Various immunotherapy approaches like immune checkpoint inhibitors, dendritic cell (DC)-based vaccines, adoptive T-cell therapy, oncolytic viruses, and combination therapies are currently used to target the CSCs. Also, recent multi-omic technologies can divulge exclusive CSC-associated cell surface markers, which can be used in detection or therapeutics of CSCs for various cancers. Additionally, detection of CSC-specific neoantigens can help in the design of new immunotherapeutics for cancers. Available literature suggests that many types of cancers have CSCs located in anatomically distinct niches within the tumor microenvironment (TME), which help in CSC’s survival and maintenance. Unique pro-survival and anti-survival intercellular and intracellular cross talk also exists among the CSCs, its niche and/or TME. Modulating unique CSC-niche/TME interaction(s) can reduce the maintenance potential of CSCs, and thereby prevent tumor development and progression or cancer metastasis. Many important cell signaling pathways play a key role in the maintenance and regulation of CSCs. Several new potential therapeutic molecules that could specifically target the CSCs or their signaling pathways to overcome cancer metastasis, treatment-resistance or relapse, are being developed. Furthermore, the emerging clinical studies strongly support the use of drugs as a monotherapy or in combination with other available standard therapies. This chapter highlights the roles of various critical CSC markers and pathways in or around the CSCs, and the several CSC-targeting approaches or therapies that are used or being developed to treat cancer for a cure.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Pineros M, Znaor A, Bray F (2019) Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer 144(8):1941–1953
Fisher R, Pusztai L, Swanton C (2013) Cancer heterogeneity: implications for targeted therapeutics. Br J Cancer 108(3):479–485
Morrison SJ, Weissman IL (1994) The long-term repopulating subset of hematopoietic stem cells is deterministic and isolatable by phenotype. Immunity 1(8):661–673
Reya T, Morrison SJ, Clarke MF, Weissman IL (2001) Stem cells, cancer, and cancer stem cells. Nature 414(6859):105–111
Campbell LL, Polyak K (2007) Breast tumor heterogeneity: cancer stem cells or clonal evolution? Cell Cycle 6(19):2332–2338
Phi LTH, Sari IN, Yang YG, Lee SH, Jun N, Kim KS, Lee YK, Kwon HY (2018) Cancer stem cells (CSCs) in drug resistance and their therapeutic implications in cancer treatment. Stem Cells Int 2018:5416923
Saygin C, Matei D, Majeti R, Reizes O, Lathia JD (2019) Targeting cancer stemness in the clinic: from hype to hope. Cell Stem Cell 24(1):25–40
Shibata M, Hoque MO (2019) Targeting cancer stem cells: a strategy for effective eradication of cancer. Cancers (Basel) 11(5):172
Sun HR, Wang S, Yan SC, Zhang Y, Nelson PJ, Jia HL, Qin LX, Dong QZ (2019) Therapeutic strategies targeting cancer stem cells and their microenvironment. Front Oncol 9:1104
Amaravadi RK, Kimmelman AC, Debnath J (2019) Targeting autophagy in cancer: recent advances and future directions. Cancer Discov 9(9):1167–1181
Rabu C, Rangan L, Florenceau L, Fortun A, Charpentier M, Dupre E, Paolini L, Beauvillain C, Dupel E, Latouche JB, Adotevi O, Labarriere N, Lang F (2019) Cancer vaccines: designing artificial synthetic long peptides to improve presentation of class I and class II T cell epitopes by dendritic cells. Onco Targets Ther 8(4):e1560919
Fessler E, Dijkgraaf FE, Felipe De Sousa EM, Medema JP (2013) Cancer stem cell dynamics in tumor progression and metastasis: is the microenvironment to blame? Cancer Lett 341(1):97–104
Nassar D, Blanpain C (2016) Cancer stem cells: basic concepts and therapeutic implications. Annu Rev Pathol 11:47–76
Badrinath N, Yoo SY (2019) Recent advances in cancer stem cell-targeted immunotherapy. Cancers (Basel) 11(3):310
Capp JP (2019) Cancer stem cells: from historical roots to a new perspective. J Oncol 2019:5189232
Riha R, Gupta-Saraf P, Bhanja P, Badkul S, Saha S (2017) Stressed out – therapeutic implications of ER stress related cancer research. Onco Targets Ther 2:156–167
Corazzari M, Gagliardi M, Fimia GM, Piacentini M (2017) Endoplasmic reticulum stress, unfolded protein response, and cancer cell fate. Front Oncol 7:78
Bhardwaj M, Leli NM, Koumenis C, Amaravadi RK (2019) Regulation of autophagy by canonical and non-canonical ER stress responses. Semin Cancer Biol 219:S1044-579X(19)30394-3
Behrends C, Sowa ME, Gygi SP, Harper JW (2010) Network organization of the human autophagy system. Nature 466(7302):68–76
Krebs J, Agellon LB, Michalak M (2015) Ca(2+) homeostasis and endoplasmic reticulum (ER) stress: an integrated view of calcium signaling. Biochem Biophys Res Commun 460(1):114–121
Fujimoto A, Kawana K, Taguchi A, Adachi K, Sato M, Nakamura H, Ogishima J, Yoshida M, Inoue T, Nishida H, Tomio K, Yamashita A, Matsumoto Y, Arimoto T, Wada-Hiraike O, Oda K, Nagamatsu T, Osuga Y, Fujii T (2016) Inhibition of endoplasmic reticulum (ER) stress sensors sensitizes cancer stem-like cells to ER stress-mediated apoptosis. Oncotarget 7(32):51854–51864
Sharif T, Martell E, Dai C, Kennedy BE, Murphy P, Clements DR, Kim Y, Lee PW, Gujar SA (2017) Autophagic homeostasis is required for the pluripotency of cancer stem cells. Autophagy 13(2):264–284
Espina V, Mariani BD, Gallagher RI, Tran K, Banks S, Wiedemann J, Huryk H, Mueller C, Adamo L, Deng J, Petricoin EF, Pastore L, Zaman S, Menezes G, Mize J, Johal J, Edmiston K, Liotta LA (2010) Malignant precursor cells pre-exist in human breast DCIS and require autophagy for survival. PLoS One 5(4):e10240
Gong C, Bauvy C, Tonelli G, Yue W, Delomenie C, Nicolas V, Zhu Y, Domergue V, Marin-Esteban V, Tharinger H, Delbos L, Gary-Gouy H, Morel AP, Ghavami S, Song E, Codogno P, Mehrpour M (2013) Beclin 1 and autophagy are required for the tumorigenicity of breast cancer stem-like/progenitor cells. Oncogene 32(18):2261–2272
Cufi S, Vazquez-Martin A, Oliveras-Ferraros C, Martin-Castillo B, Vellon L, Menendez JA (2011) Autophagy positively regulates the CD44(+) CD24(−/low) breast cancer stem-like phenotype. Cell Cycle 10(22):3871–3885
Gupta PB, Fillmore CM, Jiang G, Shapira SD, Tao K, Kuperwasser C, Lander ES (2011) Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell 146(4):633–644
Wolf J, Dewi DL, Fredebohm J, Muller-Decker K, Flechtenmacher C, Hoheisel JD, Boettcher M (2013) A mammosphere formation RNAi screen reveals that ATG4A promotes a breast cancer stem-like phenotype. Breast Cancer Res 15(6):R109
Maycotte P, Gearheart CM, Barnard R, Aryal S, Mulcahy Levy JM, Fosmire SP, Hansen RJ, Morgan MJ, Porter CC, Gustafson DL, Thorburn A (2014) STAT3-mediated autophagy dependence identifies subtypes of breast cancer where autophagy inhibition can be efficacious. Cancer Res 74(9):2579–2590
Yeo SK, Wen J, Chen S, Guan JL (2016) Autophagy differentially regulates distinct breast cancer stem-like cells in murine models via EGFR/Stat3 and Tgfbeta/Smad signaling. Cancer Res 76(11):3397–3410
Yeo SK, Guan JL (2016) Hierarchical heterogeneity in mammary tumors and its regulation by autophagy. Autophagy 12(10):1960–1961
Chaffer CL, Brueckmann I, Scheel C, Kaestli AJ, Wiggins PA, Rodrigues LO, Brooks M, Reinhardt F, Su Y, Polyak K, Arendt LM, Kuperwasser C, Bierie B, Weinberg RA (2011) Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc Natl Acad Sci U S A 108(19):7950–7955
May CD, Sphyris N, Evans KW, Werden SJ, Guo W, Mani SA (2011) Epithelial-mesenchymal transition and cancer stem cells: a dangerously dynamic duo in breast cancer progression. Breast Cancer Res 13(1):202
Ye X, Tam WL, Shibue T, Kaygusuz Y, Reinhardt F, Ng Eaton E, Weinberg RA (2015) Distinct EMT programs control normal mammary stem cells and tumour-initiating cells. Nature 525(7568):256–260
Kiyono K, Suzuki HI, Matsuyama H, Morishita Y, Komuro A, Kano MR, Sugimoto K, Miyazono K (2009) Autophagy is activated by TGF-beta and potentiates TGF-beta-mediated growth inhibition in human hepatocellular carcinoma cells. Cancer Res 69(23):8844–8852
Li J, Yang B, Zhou Q, Wu Y, Shang D, Guo Y, Song Z, Zheng Q, Xiong J (2013) Autophagy promotes hepatocellular carcinoma cell invasion through activation of epithelial-mesenchymal transition. Carcinogenesis 34(6):1343–1351
Zhu H, Wang D, Liu Y, Su Z, Zhang L, Chen F, Zhou Y, Wu Y, Yu M, Zhang Z, Shao G (2013) Role of the hypoxia-inducible factor-1 alpha induced autophagy in the conversion of non-stem pancreatic cancer cells into CD133+ pancreatic cancer stem-like cells. Cancer Cell Int 13(1):119
Song YJ, Zhang SS, Guo XL, Sun K, Han ZP, Li R, Zhao QD, Deng WJ, Xie XQ, Zhang JW, Wu MC, Wei LX (2013) Autophagy contributes to the survival of CD133+ liver cancer stem cells in the hypoxic and nutrient-deprived tumor microenvironment. Cancer Lett 339(1):70–81
Ojha R, Singh SK, Bhattacharyya S (2016) JAK-mediated autophagy regulates stemness and cell survival in cisplatin resistant bladder cancer cells. Biochim Biophys Acta 1860(11 Pt A):2484–2497
Roy BC, Ahmed I, Ramalingam S, Jala V, Haribabu B, Ramamoorthy P, Ashcraft J, Valentino J, Anant S, Sampath V, Umar S (2019) Co-localization of autophagy-related protein p62 with cancer stem cell marker dclk1 may hamper dclk1’s elimination during colon cancer development and progression. Oncotarget 10(24):2340–2354
Bellodi C, Lidonnici MR, Hamilton A, Helgason GV, Soliera AR, Ronchetti M, Galavotti S, Young KW, Selmi T, Yacobi R, Van Etten RA, Donato N, Hunter A, Dinsdale D, Tirro E, Vigneri P, Nicotera P, Dyer MJ, Holyoake T, Salomoni P, Calabretta B (2009) Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells. J Clin Invest 119(5):1109–1123
Buccarelli M, Marconi M, Pacioni S, De Pascalis I, D'Alessandris QG, Martini M, Ascione B, Malorni W, Larocca LM, Pallini R, Ricci-Vitiani L, Matarrese P (2018) Inhibition of autophagy increases susceptibility of glioblastoma stem cells to temozolomide by igniting ferroptosis. Cell Death Dis 9(8):841
Hasmim M, Janji B, Khaled M, Noman MZ, Louache F, Bordereaux D, Abderamane A, Baud V, Mami-Chouaib F, Chouaib S (2017) Cutting edge: NANOG activates autophagy under hypoxic stress by binding to BNIP3L promoter. J Immunol 198(4):1423–1428
Perez-Hernandez M, Arias A, Martinez-Garcia D, Perez-Tomas R, Quesada R, Soto-Cerrato V (2019) Targeting autophagy for cancer treatment and tumor chemosensitization. Cancers (Basel) 11(10):1599
Bedoya V (1970) Effect of chloroquine on malignant lymphoreticular and pigmented cells in vitro. Cancer Res 30(5):1262–1275
Amaravadi RK, Winkler JD (2012) Lys05: a new lysosomal autophagy inhibitor. Autophagy 8(9):1383–1384
Cechakova L, Ondrej M, Pavlik V, Jost P, Cizkova D, Bezrouk A, Pejchal J, Amaravadi RK, Winkler JD, Tichy A (2019) A potent autophagy inhibitor (Lys05) enhances the impact of ionizing radiation on human lung cancer cells H1299. Int J Mol Sci 20(23):5881
Rebecca VW, Nicastri MC, McLaughlin N, Fennelly C, McAfee Q, Ronghe A, Nofal M, Lim CY, Witze E, Chude CI, Zhang G, Alicea GM, Piao S, Murugan S, Ojha R, Levi SM, Wei Z, Barber-Rotenberg JS, Murphy ME, Mills GB, Lu Y, Rabinowitz J, Marmorstein R, Liu Q, Liu S, Xu X, Herlyn M, Zoncu R, Brady DC, Speicher DW, Winkler JD, Amaravadi RK (2017) A unified approach to targeting the lysosome’s degradative and growth signaling roles. Cancer Discov 7(11):1266–1283
Cannon MJ, Block MS, Morehead LC, Knutson KL (2019) The evolving clinical landscape for dendritic cell vaccines and cancer immunotherapy. Immunotherapy 11(2):75–79
Garg AD, Coulie PG, Van den Eynde BJ, Agostinis P (2017) Integrating next-generation dendritic cell vaccines into the current cancer immunotherapy landscape. Trends Immunol 38(8):577–593
Sabado RL, Balan S, Bhardwaj N (2017) Dendritic cell-based immunotherapy. Cell Res 27(1):74–95
Bol KF, Schreibelt G, Gerritsen WR, de Vries IJ, Figdor CG (2016) Dendritic cell-based immunotherapy: state of the art and beyond. Clin Cancer Res 22(8):1897–1906
Ning N, Pan Q, Zheng F, Teitz-Tennenbaum S, Egenti M, Ginestier C, Wicha M, Moyer J, Prince M, Chang AR, Li Q (2012) Cancer stem cell vaccination confers significant anti-tumor immunity by selectively targeting cancer stem cells. J Clin Immunol 32(2):358–358
Yin T, Shi PF, Gou SM, Shen Q, Wang CY (2014) Dendritic cells loaded with pancreatic cancer stem cells (CSCs) lysates induce antitumor immune killing effect in vitro. PLoS One 9(12):e114581
Lu L, Tao HM, Chang AE, Hu YY, Shu GS, Chen QN, Egenti M, Owen J, Moyer JS, Prince MEP, Huang S, Wicha MS, Xia JC, Li Q (2015) Cancer stem cell vaccine inhibits metastases of primary tumors and induces humoral immune responses against cancer stem cells. Onco Targets Ther 4(3):e990767
Dashti A, Ebrahimi M, Hadjati J, Memarnejadian A, Moazzeni SM (2016) Dendritic cell based immunotherapy using tumor stem cells mediates potent antitumor immune responses. Cancer Lett 374(1):175–185
Hu YY, Lu L, Xia Y, Chen X, Chang AE, Hollingsworth RE, Hurt E, Owen J, Moyer JS, Prince MEP, Dai F, Bao YY, Wang Y, Whitfield J, Xia JC, Huang S, Wicha MS, Li Q (2016) Therapeutic efficacy of cancer stem cell vaccines in the adjuvant setting. Cancer Res 76(16):4661–4672
Wefers C, Schreibelt G, Massuger LFAG, de Vries IJM, Torensma R (2018) Immune curbing of cancer stem cells by CTLs directed to NANOG. Front Immunol 9:1412
Calmeiro J, Carrascal M, Mendes L, Duarte IF, Gomes C, Serra J, Falcao A, Cruz MT, Neves BM (2019) Development of a novel dendritic cell-based immunotherapy targeting cancer stem cells. J Clin Oncol 37(15):e14009
Pang YB, He J, Cui BY, Xu S, Li XL, Wu MY, Liang R, Feng Y, Guo X, Zhang XH, Luo XL (2019) A potential antitumor effect of dendritic cells fused with cancer stem cells in hepatocellular carcinoma. Stem Cells Int 2019:Article ID 5680327
Tettamanti S, Marin V, Pizzitola I, Magnani CF, Giordano Attianese GM, Cribioli E, Maltese F, Galimberti S, Lopez AF, Biondi A, Bonnet D, Biagi E (2013) Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor. Br J Haematol 161(3):389–401
Deng Z, Wu Y, Ma W, Zhang S, Zhang YQ (2015) Adoptive T-cell therapy of prostate cancer targeting the cancer stem cell antigen EpCAM. BMC Immunol 16:1
Hurton LV, Singh H, Najjar AM, Switzer KC, Mi T, Maiti S, Olivares S, Rabinovich B, Huls H, Forget MA, Datar V, Kebriaei P, Lee DA, Champlin RE, Cooper LJ (2016) Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells. Proc Natl Acad Sci U S A 113(48):E7788–E7797
Miyamoto S, Kochin V, Kanaseki T, Hongo A, Tokita S, Kikuchi Y, Takaya A, Hirohashi Y, Tsukahara T, Terui T, Ishitani K, Hata F, Takemasa I, Miyazaki A, Hiratsuka H, Sato N, Torigoe T (2018) The antigen ASB4 on cancer stem cells serves as a target for CTL immunotherapy of colorectal cancer. Cancer Immunol Res 6(3):358–369
Ames E, Canter RJ, Grossenbacher SK, Mac S, Chen M, Smith RC, Hagino T, Perez-Cunningham J, Sckisel GD, Urayama S, Monjazeb AM, Fragoso RC, Sayers TJ, Murphy WJ (2015) NK cells preferentially target tumor cells with a cancer stem cell phenotype. J Immunol 195(8):4010–4019
Chen HC, Joalland N, Bridgeman JS, Alchami FS, Jarry U, Khan MWA, Piggott L, Shanneik Y, Li J, Herold MJ, Herrmann T, Price DA, Gallimore AM, Clarkson RW, Scotet E, Moser B, Eberl M (2017) Synergistic targeting of breast cancer stem-like cells by human gammadelta T cells and CD8(+) T cells. Immunol Cell Biol 95(7):620–629
Ferreira-Teixeira M, Paiva-Oliveira D, Parada B, Alves V, Sousa V, Chijioke O, Munz C, Reis F, Rodrigues-Santos P, Gomes C (2016) Natural killer cell-based adoptive immunotherapy eradicates and drives differentiation of chemoresistant bladder cancer stem-like cells. BMC Med 14:163
Mullen JT, Tanabe KK (2002) Viral oncolysis. Oncologist 7(2):106–119
Harrington K, Freeman DJ, Kelly B, Harper J, Soria JC (2019) Optimizing oncolytic virotherapy in cancer treatment. Nat Rev Drug Discov 18(9):689–706
Russell SJ, Peng KW, Bell JC (2012) Oncolytic virotherapy. Nat Biotechnol 30(7):658–670
Chaurasiya S, Chen NG, Warner SG (2018) Oncolytic virotherapy versus cancer stem cells: a review of approaches and mechanisms. Cancers (Basel) 10(4):124
Zhang X, Komaki R, Wang L, Fang B, Chang JY (2008) Treatment of radioresistant stem-like esophageal cancer cells by an apoptotic gene-armed, telomerase-specific oncolytic adenovirus. Clin Cancer Res 14(9):2813–2823
Cheema TA, Wakimoto H, Fecci PE, Ning J, Kuroda T, Jeyaretna DS, Martuza RL, Rabkin SD (2013) Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model. Proc Natl Acad Sci U S A 110(29):12006–12011
Yano S, Tazawa H, Hashimoto Y, Shirakawa Y, Kuroda S, Nishizaki M, Kishimoto H, Uno F, Nagasaka T, Urata Y, Kagawa S, Hoffman RM, Fujiwara T (2013) A genetically engineered oncolytic adenovirus decoys and lethally traps quiescent cancer stem-like cells in S/G2/M phases. Clin Cancer Res 19(23):6495–6505
Sato-Dahlman M, Miura Y, Huang JL, Hajeri P, Jacobsen K, Davydova J, Yamamoto M (2017) CD133-targeted oncolytic adenovirus demonstrates anti-tumor effect in colorectal cancer. Oncotarget 8(44):76044–76056
Wang H, Chen NG, Minev BR, Szalay AA (2012) Oncolytic vaccinia virus GLV-1h68 strain shows enhanced replication in human breast cancer stem-like cells in comparison to breast cancer cells. J Transl Med 10(1):167
Wang J, Sullenger BA, Rich JN (2012) Notch signaling in cancer stem cells. Adv Exp Med Biol 727:174–185
Gil M, Komorowski MP, Seshadri M, Rokita H, McGray AJ, Opyrchal M, Odunsi KO, Kozbor D (2014) CXCL12/CXCR4 blockade by oncolytic virotherapy inhibits ovarian cancer growth by decreasing immunosuppression and targeting cancer-initiating cells. J Immunol 193(10):5327–5337
Yoo SY, Bang SY, Jeong SN, Kang DH, Heo J (2016) A cancer-favoring oncolytic vaccinia virus shows enhanced suppression of stem-cell like colon cancer. Oncotarget 7(13):16479–16489
Zhang ZY, Zheng SH, Yang WG, Yang C, Yuan WT (2017) Targeting colon cancer stem cells with novel blood cholesterol drug pitavastatin. Eur Rev Med Pharmacol Sci 21(6):1226–1233
Saha D, Martuza RL, Rabkin SD (2017) Macrophage polarization contributes to glioblastoma eradication by combination immunovirotherapy and immune checkpoint blockade. Cancer Cell 32(2):253–267
Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, Minden M, Paterson B, Caligiuri MA, Dick JE (1994) A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367(6464):645–648
Gerlinger M, Rowan AJ, Horswell S, Math M, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P, Varela I, Phillimore B, Begum S, McDonald NQ, Butler A, Jones D, Raine K, Latimer C, Santos CR, Nohadani M, Eklund AC, Spencer-Dene B, Clark G, Pickering L, Stamp G, Gore M, Szallasi Z, Downward J, Futreal PA, Swanton C (2012) Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366(10):883–892
Najafi M, Mortezaee K, Majidpoor J (2019) Cancer stem cell (CSC) resistance drivers. Life Sci 234:116781
Klonisch T, Wiechec E, Hombach-Klonisch S, Ande SR, Wesselborg S, Schulze-Osthoff K, Los M (2008) Cancer stem cell markers in common cancers – therapeutic implications. Trends Mol Med 14(10):450–460
Yadav AK, Desai NS (2019) Cancer stem cells: acquisition, characteristics, therapeutic implications, targeting strategies and future prospects. Stem Cell Rev Rep 15(3):331–355
Turdo A, Veschi V, Gaggianesi M, Chinnici A, Bianca P, Todaro M, Stassi G (2019) Meeting the challenge of targeting cancer stem cells. Front Cell Dev Biol 7:16
Schmohl JU, Vallera DA (2016) CD133, selectively targeting the root of cancer. Toxins (Basel) 8(6):165
Damek-Poprawa M, Volgina A, Korostoff J, Sollecito TP, Brose MS, O'Malley BW Jr, Akintoye SO, DiRienzo JM (2011) Targeted inhibition of CD133+ cells in oral cancer cell lines. J Dent Res 90(5):638–645
Skubitz AP, Taras EP, Boylan KL, Waldron NN, Oh S, Panoskaltsis-Mortari A, Vallera DA (2013) Targeting CD133 in an in vivo ovarian cancer model reduces ovarian cancer progression. Gynecol Oncol 130(3):579–587
Monzani E, Facchetti F, Galmozzi E, Corsini E, Benetti A, Cavazzin C, Gritti A, Piccinini A, Porro D, Santinami M, Invernici G, Parati E, Alessandri G, La Porta CA (2007) Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. Eur J Cancer 43(5):935–946
Ohlfest JR, Zellmer DM, Panyam J, Swaminathan SK, Oh S, Waldron NN, Toma S, Vallera DA (2013) Immunotoxin targeting CD133(+) breast carcinoma cells. Drug Deliv Transl Res 3(2):195–204
Waldron NN, Barsky SH, Dougherty PR, Vallera DA (2014) A bispecific EpCAM/CD133-targeted toxin is effective against carcinoma. Target Oncol 9(3):239–249
Huang J, Li C, Wang Y, Lv H, Guo Y, Dai H, Wicha MS, Chang AE, Li Q (2013) Cytokine-induced killer (CIK) cells bound with anti-CD3/anti-CD133 bispecific antibodies target CD133(high) cancer stem cells in vitro and in vivo. Clin Immunol 149(1):156–168
Swaminathan SK, Roger E, Toti U, Niu L, Ohlfest JR, Panyam J (2013) CD133-targeted paclitaxel delivery inhibits local tumor recurrence in a mouse model of breast cancer. J Control Release 171(3):280–287
Vallera DA, Zhang B, Gleason MK, Oh S, Weiner LM, Kaufman DS, McCullar V, Miller JS, Verneris MR (2013) Heterodimeric bispecific single-chain variable-fragment antibodies against EpCAM and CD16 induce effective antibody-dependent cellular cytotoxicity against human carcinoma cells. Cancer Biother Radiopharm 28(4):274–282
Schmohl JU, Gleason MK, Dougherty PR, Miller JS, Vallera DA (2016) Heterodimeric bispecific single chain variable fragments (scFv) killer engagers (BiKEs) enhance NK-cell activity against CD133+ colorectal cancer cells. Target Oncol 11(3):353–361
Chen C, Zhao S, Karnad A, Freeman JW (2018) The biology and role of CD44 in cancer progression: therapeutic implications. J Hematol Oncol 11(1):64
Sun BS, Li Y, Zhang ZF, You J, Wang CL (2013) Osteopontin combined with CD44v6, a novel prognostic biomarker in non-small cell lung cancer undergoing curative resection. Ann Thorac Surg 96(6):1943–1951
Castella EM, Ariza A, Pellicer I, Fernandez-Vasalo A, Ojanguren I (1998) Differential expression of CD44v6 in metastases of intestinal and diffuse types of gastric carcinoma. J Clin Pathol 51(2):134–137
Thapa R, Wilson GD (2016) The importance of CD44 as a stem cell biomarker and therapeutic target in cancer. Stem Cells Int 2016:2087204
Hirata K, Suzuki H, Imaeda H, Matsuzaki J, Tsugawa H, Nagano O, Asakura K, Saya H, Hibi T (2013) CD44 variant 9 expression in primary early gastric cancer as a predictive marker for recurrence. Br J Cancer 109(2):379–386
Ma L, Dong L, Chang P (2019) CD44v6 engages in colorectal cancer progression. Cell Death Dis 10(1):30
Lau WM, Teng E, Chong HS, Lopez KA, Tay AY, Salto-Tellez M, Shabbir A, So JB, Chan SL (2014) CD44v8-10 is a cancer-specific marker for gastric cancer stem cells. Cancer Res 74(9):2630–2641
Jin L, Hope KJ, Zhai Q, Smadja-Joffe F, Dick JE (2006) Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med 12(10):1167–1174
Krause DS, Lazarides K, von Andrian UH, Van Etten RA (2006) Requirement for CD44 in homing and engraftment of BCR-ABL-expressing leukemic stem cells. Nat Med 12(10):1175–1180
Verel I, Heider KH, Siegmund M, Ostermann E, Patzelt E, Sproll M, Snow GB, Adolf GR, van Dongen GA (2002) Tumor targeting properties of monoclonal antibodies with different affinity for target antigen CD44V6 in nude mice bearing head-and-neck cancer xenografts. Int J Cancer 99(3):396–402
Borjesson PK, Postema EJ, Roos JC, Colnot DR, Marres HA, van Schie MH, Stehle G, de Bree R, Snow GB, Oyen WJ, van Dongen GA (2003) Phase I therapy study with (186)Re-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with head and neck squamous cell carcinoma. Clin Cancer Res 9(10 Pt 2):3961S–3972S
Tijink BM, Buter J, de Bree R, Giaccone G, Lang MS, Staab A, Leemans CR, van Dongen GA (2006) A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus. Clin Cancer Res 12(20 Pt 1):6064–6072
Yang Y, Zhao X, Li X, Yan Z, Liu Z, Li Y (2017) Effects of anti-CD44 monoclonal antibody IM7 carried with chitosan polylactic acid-coated nano-particles on the treatment of ovarian cancer. Oncol Lett 13(1):99–104
Su Z, Liu D, Chen L, Zhang J, Ru L, Chen Z, Gao Z, Wang X (2019) CD44-targeted magnetic nanoparticles kill head and neck squamous cell carcinoma stem cells in an alternating magnetic field. Int J Nanomedicine 14:7549–7560
Chen H, Lin J, Shan Y, Zhengmao L (2019) The promotion of nanoparticle delivery to two populations of gastric cancer stem cells by CD133 and CD44 antibodies. Biomed Pharmacother 115:108857
Sanginario A, Miccoli B, Demarchi D (2017) Carbon nanotubes as an effective opportunity for cancer diagnosis and treatment. Biosensors 7(4):9
Yang Y, Long Y, Wang Y, Ren K, Li M, Zhang Z, Xiang B, He Q (2020) Enhanced anti-tumor and anti-metastasis therapy for triple negative breast cancer by CD44 receptor-targeted hybrid self-delivery micelles. Int J Pharm 577:119085
Gautam M, Thapa RK, Gupta B, Soe ZC, Ou W, Poudel K, Jin SG, Choi HG, Yong CS, Kim JO (2020) Phytosterol-loaded CD44 receptor-targeted PEGylated nano-hybrid phyto-liposomes for synergistic chemotherapy. Expert Opin Drug Deliv 17(3):423–434
Liang X, Li X, Duan J, Chen Y, Wang X, Pang L, Kong D, Song B, Li C, Yang J (2018) Nanoparticles with CD44 targeting and ROS triggering properties as effective in vivo antigen delivery system. Mol Pharm 15(2):508–518
Plaks V, Kong N, Werb Z (2015) The cancer stem cell niche: how essential is the niche in regulating stemness of tumor cells? Cell Stem Cell 16(3):225–238
Hanahan D, Coussens LM (2012) Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 21(3):309–322
Clara JA, Monge C, Yang Y, Takebe N (2019) Targeting signalling pathways and the immune microenvironment of cancer stem cells - a clinical update. Nat Rev Clin Oncol 17(4):204–232
Doglioni G, Parik S, Fendt SM (2019) Interactions in the (pre)metastatic niche support metastasis formation. Front Oncol 9:219
Nwabo Kamdje AH, Takam Kamga P, Tagne Simo R, Vecchio L, Seke Etet PF, Muller JM, Bassi G, Lukong E, Kumar Goel R, Mbo Amvene J, Krampera M (2017) Developmental pathways associated with cancer metastasis: notch, Wnt, and Hedgehog. Cancer Biol Med 14(2):109–120
Li L, Tang P, Li S, Qin X, Yang H, Wu C, Liu Y (2017) Notch signaling pathway networks in cancer metastasis: a new target for cancer therapy. Med Oncol 34(10):180
Hu YY, Zheng MH, Zhang R, Liang YM, Han H (2012) Notch signaling pathway and cancer metastasis. Adv Exp Med Biol 727:186–198
Zhan T, Rindtorff N, Boutros M (2017) Wnt signaling in cancer. Oncogene 36(11):1461–1473
Zeng S, Seifert AM, Zhang JQ, Cavnar MJ, Kim TS, Balachandran VP, Santamaria-Barria JA, Cohen NA, Beckman MJ, Medina BD, Rossi F, Crawley MH, Loo JK, Maltbaek JH, Besmer P, Antonescu CR, DeMatteo RP (2017) Wnt/beta-catenin signaling contributes to tumor malignancy and is targetable in gastrointestinal stromal tumor. Mol Cancer Ther 16(9):1954–1966
Sari IN, Phi LTH, Jun N, Wijaya YT, Lee S, Kwon HY (2018) Hedgehog signaling in cancer: a prospective therapeutic target for eradicating cancer stem cells. Cells 7(11):208
Niyaz M, Khan MS, Mudassar S (2019) Hedgehog signaling: an Achilles’ heel in cancer. Transl Oncol 12(10):1334–1344
Warren JSA, Xiao Y, Lamar JM (2018) YAP/TAZ activation as a target for treating metastatic cancer. Cancers (Basel) 10(4):115
Elaimy AL, Mercurio AM (2018) Convergence of VEGF and YAP/TAZ signaling: Implications for angiogenesis and cancer biology. Sci Signal 11(552):eaau1165
Piccolo S, Dupont S, Cordenonsi M (2014) The biology of YAP/TAZ: hippo signaling and beyond. Physiol Rev 94(4):1287–1312
Matsui WH (2016) Cancer stem cell signaling pathways. Medicine (Baltimore) 95(1 Suppl 1):S8–S19
Von Hoff DD, LoRusso PM, Rudin CM, Reddy JC, Yauch RL, Tibes R, Weiss GJ, Borad MJ, Hann CL, Brahmer JR, Mackey HM, Lum BL, Darbonne WC, Marsters JC Jr, de Sauvage FJ, Low JA (2009) Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med 361(12):1164–1172
Dummer R, Guminski A, Gutzmer R, Dirix L, Lewis KD, Combemale P, Herd RM, Kaatz M, Loquai C, Stratigos AJ, Schulze HJ, Plummer R, Gogov S, Pallaud C, Yi T, Mone M, Chang AL, Cornelis F, Kudchadkar R, Trefzer U, Lear JT, Sellami D, Migden MR (2016) The 12-month analysis from basal cell carcinoma outcomes with LDE225 treatment (BOLT): a phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma. J Am Acad Dermatol 75(1):113–125
Sekulic A, Migden MR, Oro AE, Dirix L, Lewis KD, Hainsworth JD, Solomon JA, Yoo S, Arron ST, Friedlander PA, Marmur E, Rudin CM, Chang AL, Low JA, Mackey HM, Yauch RL, Graham RA, Reddy JC, Hauschild A (2012) Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med 366(23):2171–2179
Chang AL, Solomon JA, Hainsworth JD, Goldberg L, McKenna E, Day BM, Chen DM, Weiss GJ (2014) Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib. J Am Acad Dermatol 70(1):60–69
Robinson GW, Orr BA, Wu G, Gururangan S, Lin T, Qaddoumi I, Packer RJ, Goldman S, Prados MD, Desjardins A, Chintagumpala M, Takebe N, Kaste SC, Rusch M, Allen SJ, Onar-Thomas A, Stewart CF, Fouladi M, Boyett JM, Gilbertson RJ, Curran T, Ellison DW, Gajjar A (2015) Vismodegib exerts targeted efficacy against recurrent sonic hedgehog-subgroup medulloblastoma: results from phase II pediatric brain tumor consortium studies PBTC-025B and PBTC-032. J Clin Oncol 33(24):2646–2654
Berlin J, Bendell JC, Hart LL, Firdaus I, Gore I, Hermann RC, Mulcahy MF, Zalupski MM, Mackey HM, Yauch RL, Graham RA, Bray GL, Low JA (2013) A randomized phase II trial of vismodegib versus placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic colorectal cancer. Clin Cancer Res 19(1):258–267
Belani CP, Dahlberg SE, Rudin CM, Fleisher M, Chen HX, Takebe N, Velasco MR Jr, Tester WJ, Sturtz K, Hann CL, Shanks JC, Monga M, Ramalingam SS, Schiller JH (2016) Vismodegib or cixutumumab in combination with standard chemotherapy for patients with extensive-stage small cell lung cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1508). Cancer 122(15):2371–2378
Catenacci DV, Junttila MR, Karrison T, Bahary N, Horiba MN, Nattam SR, Marsh R, Wallace J, Kozloff M, Rajdev L, Cohen D, Wade J, Sleckman B, Lenz HJ, Stiff P, Kumar P, Xu P, Henderson L, Takebe N, Salgia R, Wang X, Stadler WM, de Sauvage FJ, Kindler HL (2015) Randomized phase Ib/II study of gemcitabine plus placebo or vismodegib, a hedgehog pathway inhibitor, in patients with metastatic pancreatic cancer. J Clin Oncol 33(36):4284–4292
Sharpe HJ, Pau G, Dijkgraaf GJ, Basset-Seguin N, Modrusan Z, Januario T, Tsui V, Durham AB, Dlugosz AA, Haverty PM, Bourgon R, Tang JY, Sarin KY, Dirix L, Fisher DC, Rudin CM, Sofen H, Migden MR, Yauch RL, de Sauvage FJ (2015) Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma. Cancer Cell 27(3):327–341
Fernandez-Valdivia R, Takeuchi H, Samarghandi A, Lopez M, Leonardi J, Haltiwanger RS, Jafar-Nejad H (2011) Regulation of mammalian Notch signaling and embryonic development by the protein O-glucosyltransferase Rumi. Development 138(10):1925–1934
Cook N, Basu B, Smith DM, Gopinathan A, Evans J, Steward WP, Palmer D, Propper D, Venugopal B, Hategan M, Anthoney DA, Hampson LV, Nebozhyn M, Tuveson D, Farmer-Hall H, Turner H, McLeod R, Halford S, Jodrell D (2018) A phase I trial of the gamma-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma. Br J Cancer 118(6):793–801
Krop I, Demuth T, Guthrie T, Wen PY, Mason WP, Chinnaiyan P, Butowski N, Groves MD, Kesari S, Freedman SJ, Blackman S, Watters J, Loboda A, Podtelezhnikov A, Lunceford J, Chen C, Giannotti M, Hing J, Beckman R, Lorusso P (2012) Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors. J Clin Oncol 30(19):2307–2313
Fouladi M, Stewart CF, Olson J, Wagner LM, Onar-Thomas A, Kocak M, Packer RJ, Goldman S, Gururangan S, Gajjar A, Demuth T, Kun LE, Boyett JM, Gilbertson RJ (2011) Phase I trial of MK-0752 in children with refractory CNS malignancies: a pediatric brain tumor consortium study. J Clin Oncol 29(26):3529–3534
Schott AF, Landis MD, Dontu G, Griffith KA, Layman RM, Krop I, Paskett LA, Wong H, Dobrolecki LE, Lewis MT, Froehlich AM, Paranilam J, Hayes DF, Wicha MS, Chang JC (2013) Preclinical and clinical studies of gamma secretase inhibitors with docetaxel on human breast tumors. Clin Cancer Res 19(6):1512–1524
Pant S, Jones SF, Kurkjian CD, Infante JR, Moore KN, Burris HA, McMeekin DS, Benhadji KA, Patel BKR, Frenzel MJ, Kursar JD, Zamek-Gliszczynski MJ, Yuen ESM, Chan EM, Bendell JC (2016) A first-in-human phase I study of the oral Notch inhibitor, LY900009, in patients with advanced cancer. Eur J Cancer 56:1–9
Massard C, Azaro A, Soria JC, Lassen U, Le Tourneau C, Sarker D, Smith C, Ohnmacht U, Oakley G, Patel BKR, Yuen ESM, Benhadji KA, Rodon J (2018) First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer. Ann Oncol 29(9):1911–1917
Smith DC, Eisenberg PD, Manikhas G, Chugh R, Gubens MA, Stagg RJ, Kapoun AM, Xu L, Dupont J, Sikic B (2014) A phase I dose escalation and expansion study of the anticancer stem cell agent demcizumab (anti-DLL4) in patients with previously treated solid tumors. Clin Cancer Res 20(24):6295–6303
Yen WC, Fischer MM, Axelrod F, Bond C, Cain J, Cancilla B, Henner WR, Meisner R, Sato A, Shah J, Tang T, Wallace B, Wang M, Zhang C, Kapoun AM, Lewicki J, Gurney A, Hoey T (2015) Targeting Notch signaling with a Notch2/Notch3 antagonist (tarextumab) inhibits tumor growth and decreases tumor-initiating cell frequency. Clin Cancer Res 21(9):2084–2095
Hu ZI, Bendell JC, Bullock A, LoConte NK, Hatoum H, Ritch P, Hool H, Leach JW, Sanchez J, Sohal DPS, Strickler J, Patel R, Wang-Gillam A, Firdaus I, Yu KH, Kapoun AM, Holmgren E, Zhou L, Dupont J, Picozzi V, Sahai V, O'Reilly EM (2019) A randomized phase II trial of nab-paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer. Cancer Med 8(11):5148–5157
Basu S, Haase G, Ben-Ze'ev A (2016) Wnt signaling in cancer stem cells and colon cancer metastasis. F1000Res 5:F1000
Reya T, Duncan AW, Ailles L, Domen J, Scherer DC, Willert K, Hintz L, Nusse R, Weissman IL (2003) A role for Wnt signalling in self-renewal of haematopoietic stem cells. Nature 423(6938):409–414
Malanchi I, Peinado H, Kassen D, Hussenet T, Metzger D, Chambon P, Huber M, Hohl D, Cano A, Birchmeier W, Huelsken J (2008) Cutaneous cancer stem cell maintenance is dependent on beta-catenin signalling. Nature 452(7187):650–653
Ramachandran I, Thavathiru E, Ramalingam S, Natarajan G, Mills WK, Benbrook DM, Zuna R, Lightfoot S, Reis A, Anant S, Queimado L (2012) Wnt inhibitory factor 1 induces apoptosis and inhibits cervical cancer growth, invasion and angiogenesis in vivo. Oncogene 31(22):2725–2737
Ramachandran I, Ganapathy V, Gillies E, Fonseca I, Sureban SM, Houchen CW, Reis A, Queimado L (2014) Wnt inhibitory factor 1 suppresses cancer stemness and induces cellular senescence. Cell Death Dis 5(5):e1246
Jimeno A, Gordon M, Chugh R, Messersmith W, Mendelson D, Dupont J, Stagg R, Kapoun AM, Xu L, Uttamsingh S, Brachmann RK, Smith DC (2017) A first-in-human phase I study of the anticancer stem cell agent ipafricept (OMP-54F28), a decoy receptor for Wnt ligands, in patients with advanced solid tumors. Clin Cancer Res 23(24):7490–7497
Ko AH, Chiorean EG, Kwak EL, Lenz H-J, Nadler PI, Wood DL, Fujimori M, Inada T, Kouji H, McWilliams RR (2016) Final results of a phase Ib dose-escalation study of PRI-724, a CBP/beta-catenin modulator, plus gemcitabine (GEM) in patients with advanced pancreatic adenocarcinoma (APC) as second-line therapy after FOLFIRINOX or FOLFOX. J Clin Oncol 34(15 Suppl):e15721
Hardee ME, Marciscano AE, Medina-Ramirez CM, Zagzag D, Narayana A, Lonning SM, Barcellos-Hoff MH (2012) Resistance of glioblastoma-initiating cells to radiation mediated by the tumor microenvironment can be abolished by inhibiting transforming growth factor-beta. Cancer Res 72(16):4119–4129
Penuelas S, Anido J, Prieto-Sanchez RM, Folch G, Barba I, Cuartas I, Garcia-Dorado D, Poca MA, Sahuquillo J, Baselga J, Seoane J (2009) TGF-beta increases glioma-initiating cell self-renewal through the induction of LIF in human glioblastoma. Cancer Cell 15(4):315–327
Melisi D, Garcia-Carbonero R, Macarulla T, Pezet D, Deplanque G, Fuchs M, Trojan J, Kozloff M, Simionato F, Cleverly A, Smith C, Wang S, Man M, Driscoll KE, Estrem ST, Lahn MMF, Benhadji KA, Tabernero J (2019) TGFbeta receptor inhibitor galunisertib is linked to inflammation- and remodeling-related proteins in patients with pancreatic cancer. Cancer Chemother Pharmacol 83(5):975–991
Brandes AA, Carpentier AF, Kesari S, Sepulveda-Sanchez JM, Wheeler HR, Chinot O, Cher L, Steinbach JP, Capper D, Specenier P, Rodon J, Cleverly A, Smith C, Gueorguieva I, Miles C, Guba SC, Desaiah D, Lahn MM, Wick W (2016) A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma. Neuro-Oncology 18(8):1146–1156
Stine RR, Matunis EL (2013) JAK-STAT signaling in stem cells. Adv Exp Med Biol 786:247–267
Birnie R, Bryce SD, Roome C, Dussupt V, Droop A, Lang SH, Berry PA, Hyde CF, Lewis JL, Stower MJ, Maitland NJ, Collins AT (2008) Gene expression profiling of human prostate cancer stem cells reveals a pro-inflammatory phenotype and the importance of extracellular matrix interactions. Genome Biol 9(5):R83
Zhou J, Wulfkuhle J, Zhang H, Gu P, Yang Y, Deng J, Margolick JB, Liotta LA, Petricoin E 3rd, Zhang Y (2007) Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance. Proc Natl Acad Sci U S A 104(41):16158–16163
Hart S, Goh KC, Novotny-Diermayr V, Hu CY, Hentze H, Tan YC, Madan B, Amalini C, Loh YK, Ong LC, William AD, Lee A, Poulsen A, Jayaraman R, Ong KH, Ethirajulu K, Dymock BW, Wood JW (2011) SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies. Leukemia 25(11):1751–1759
Dubrovska A, Kim S, Salamone RJ, Walker JR, Maira SM, Garcia-Echeverria C, Schultz PG, Reddy VA (2009) The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations. Proc Natl Acad Sci U S A 106(1):268–273
Acknowledgments
Our sincere appreciation to Dr. Satish Ramalingam (Department of Genetic Engineering, School of Bioengineering, SRM Institute of Science and Technology, Kanchipuram, Tamil Nadu, India) for his helpful discussion, carefully reading this book chapter and providing critical comments.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Ethics declarations
The authors declare no conflict of interest.
Rights and permissions
Copyright information
© 2020 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Paul, M.K. et al. (2020). Targeting Therapies for Cancer Stem Cells. In: Pathak, S., Banerjee, A. (eds) Cancer Stem Cells: New Horizons in Cancer Therapies. Springer, Singapore. https://doi.org/10.1007/978-981-15-5120-8_16
Download citation
DOI: https://doi.org/10.1007/978-981-15-5120-8_16
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-15-5119-2
Online ISBN: 978-981-15-5120-8
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)